NCT07835971Active, not recruitingPhase 2
A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GW906 (SAL0132) Injection in Patients With Essential Hypertension
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the effect of GW906 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of GW906.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 319 (actual)
- First submitted
- 17 Sept 2026
- Start date
- 24 Dec 2025
- Primary completion date
- 15 Sept 2026
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Diseases
- High blood pressure
- NCT number
- NCT07835971
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 319
- From 24 Dec 2025 to the primary completion date, 15 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received an investigational agent within the last 3 months.
Other illness
- Secondary hypertension.
- Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus.
- History of any cardiovascular event within 12 months.
- History of intolerance to SC injection(s).
Lab values
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5× upper limit of normal (ULN); Total bilirubin \> 1.5 × ULN; International normalized ratio (INR) \> 2.0; Serum potassium \> 5.0 mmol/L or \< 3.5 mmol/L; eGFR≤30 mL/min/1.73m\^2.
Other
- orthostatic hypotension.
Who the study is looking for
- Age ≥ 18 years and ≤ 75 years, of either sex.
- Mean sitting systolic blood pressure (msSBP) ≥ 140 mmHg and \< 180 mmHg at screening.
- Willing to participate in the study and provide written informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.